Wire · operational-macro
Is FDA Valve Repair Approval Altering The Investment Case For Edwards Lifesciences (EW)?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Edwards Lifesciences received FDA approval for its PASCAL Precision system and the PASCAL Ace with Capture Clarity system, enhancing its transcatheter mitral and tricuspid valve repair portfolio and supporting anticipated revenue and earnings growth tied to transcatheter therapy adoption in the U.S.
This Wire brief sits within Fusion42's coverage of Medtech, and 6 sources have reported it between 21 Oct 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
You have a clearer path to grow U.S. sales with Edwards’ broader toolkit for complex heart valve repair. This FDA nod invites you to target multidisciplinary heart teams expanding transcatheter programmes now.
◆ Coverage
6 sources · first reported 21 Oct 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics